| 30.10 06:24 | dpa-AFX: *BOFA RAISES INCYTE TO 'BUY' - PRICE TARGET 90 USD |
| 30.10 06:24 | dpa-AFX: *BOFA HEBT INCYTE AUF 'BUY' - ZIEL 90 USD |
| 29.10 12:37 | dpa-AFX: Incyte Corporation Q3 Profit Drops, Inline With Estimates |
| 29.10 12:13 | dpa-AFX: *INCYTE Q3 TOTAL REVENUES $1.14 BLN VS. $919.03 MLN PRIOR YEAR |
| 29.10 12:12 | dpa-AFX: *INCYTE Q3 NET INCOME $106.46 MLN VS. $171.27 MLN PRIOR YEAR |
| 29.10 12:10 | dpa-AFX: *INCYTE Q3 EPS DECLINES TO $0.54 FROM $0.76 LAST YEAR |
| 29.10 12:01 | dpa-AFX: Incyte Q3 24 Earnings Conference Call At 8:00 AM ET |
| 08.10 05:10 | dpa-AFX: *INCYTE REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE |
| 19.09 14:45 | dpa-AFX: Incyte To Present At Cantor Global Healthcare Conference; Webcast At 9:45 AM ET |
| 19.09 03:00 | dpa-AFX: Incyte: Phase 2 Trial Results Of Niktimvo In Chronic Graft-Versus-Host Disease Meet Primary Goal |
| 06.09 15:46 | dpa-AFX: Incyte To Present At Morgan Stanley Global Healthcare Conference; Webcast At 10:45 AM ET |
| 18.08 07:44 | dpa-AFX: Biotech Buzz: VIRX Cuts 23% Jobs, FDA Oks New Drug For Hypoparathyroidism, SIGA Down But Not Out |
| 30.07 13:29 | dpa-AFX: *INCYTE Q2 TOTAL REVENUES $1.044 BLN, UP 9% Y/Y |
| 30.07 13:21 | dpa-AFX: Incyte Corporation Q2 Earnings Summary |
| 30.07 13:07 | dpa-AFX: *INCYTE Q2 GAAP LOSS PER SHARE $2.04; NON-GAAP LOSS PER SHARE $1.82 |
| 30.07 10:19 | dpa-AFX: Biotech Stocks Facing FDA Decision In August 2024 |
| 29.07 10:15 | dpa-AFX: Biotech Stocks Facing FDA Decision In August 2024 |
| 13.05 16:54 | dpa-AFX: Incyte Gains 8% On Share Buy Back Authorization Of Up To $2.0 Bln |
| 13.05 16:29 | dpa-AFX: *INCYTE TO BUY BACK UP TO $2.0 BLN OF ITS COMMON STOCK |
| 30.04 13:22 | dpa-AFX: Incyte Corporation Q1 Profit Increases, but misses estimates |
|
|
